journal article·2025-08Open access

Precision‐Engineered Cobalt‐Doped Iron Oxide Nanoparticles: From Octahedron Seeds to Cubical Bipyramids for Enhanced Magnetic Hyperthermia

Prem Singh, Karthickraja Duraisamy, Constanze Raitmayr, Kongbrailatpam Shitaljit Sharma, Tetiana Korzun, Khushal Singh, Abraham S Moses, Kentaro Yamada, Vladislav Grigoriev, Ananiya A. Demessie, Youngrong Park, Yoon Tae Goo, Babak Mamnoon, Ana Paula Mesquita Souza, Kenkichi Michimoto, Khashayar Farsad, Amit Jaiswal, Olena R Taratula, Oleh Taratula

Advanced Functional Materials· Volume 35· Issue 33

Abstract

Abstract Despite notable advancements, the significantly improved yet suboptimal heating efficiency of current magnetic nanoparticles hinders the effectiveness of systemically delivered magnetic hyperthermia in reducing tumor size or halting growth. Addressing this challenge, the seed‐and‐growth thermal decomposition method has been developed to synthesize cobalt‐doped iron oxide nanoparticles (Co‐IONPs) featuring a cubical bipyramid morphology, consisting of both magnetite and maghemite phases within their nanostructure. They possess an exceptional specific absorption rate (SAR) of 14 686 ± 396 W g⁻¹ Fe, inducing a temperature rise of 3.73 °C s −1 when subjected to an alternating magnetic field (AMF, 315 kHz; 26.8 kA m −1 ). The cubical bipyramid‐shaped Co‐IONPs, functionalized with LHRH peptide, efficiently accumulate in ovarian cancer xenografts following an intravenous injection at a relatively low dose of 4 mg kg −1 , elevating intratumoral temperatures beyond 50 °C with a high heating rate. In contrast to previously reported magnetic nanoparticles with ultrahigh heating efficiency, the developed cubical bipyramid‐shaped nanoparticles effectively halt ovarian cancer tumor growth after a single 30‐min session of magnetic hyperthermia. These outcomes underscore the potential of shape‐dependent magnetic hyperthermia, where the cubical bipyramid morphology significantly enhances the heating efficiency and therapeutic efficacy of magnetic nanoparticles, improving the effectiveness of hyperthermia‐based cancer treatments.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Iron oxide chemistry and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences College of Pharmacy Oregon State University 2730 SW Moody Avenue Portland OR 97201 USA

School of Biosciences and Bioengineering Indian Institute of Technology Mandi Kamand Mandi Himachal Pradesh 175075 India

Dotter Interventional Institute Department of Interventional Radiology Oregon Health & Science University Portland OR 97239 USA

Funding

Eunice Kennedy Shriver National Institute of Child Health and Human Development · National Cancer Institute

References (89)

Show source-provided references
1. 10.1007/s11060-010-0389-010.1007/s11060-010-0389-0 ↗
2. 10.1080/0265673060117547910.1080/02656730601175479 ↗
3. 10.1080/02656736.2018.143086710.1080/02656736.2018.1430867 ↗
4. 10.1080/0265673060110603710.1080/02656730601106037 ↗
5. 10.1002/smtd.20220091610.1002/smtd.202200916 ↗
6. 10.1002/adma.20170436210.1002/adma.201704362 ↗
7. 10.1021/acsnano.8b0654210.1021/acsnano.8b06542 ↗
8. 10.1021/acs.nanolett.1c0245910.1021/acs.nanolett.1c02459 ↗
9. 10.1038/nnano.2011.9510.1038/nnano.2011.95 ↗
10. 10.3390/pharmaceutics1211102010.3390/pharmaceutics12111020 ↗
11. 10.1002/smll.20210780810.1002/smll.202107808 ↗
12. 10.7150/thno.586010.7150/thno.5860 ↗
13. 10.1038/nnano.2011.9510.1038/nnano.2011.95 ↗
14. 10.1021/acsnano.7b0275210.1021/acsnano.7b02752 ↗
15. 10.1021/acscentsci.8b0039910.1021/acscentsci.8b00399 ↗
16. 10.1021/acs.chemmater.5b0251010.1021/acs.chemmater.5b02510 ↗
17. 10.1021/ja01167a00110.1021/ja01167a001 ↗
18. 10.1021/ja970510210.1021/ja9705102 ↗
19. 10.3389/fchem.2021.62905410.3389/fchem.2021.629054 ↗
20. 10.1002/anie.20060314810.1002/anie.200603148 ↗
21. 10.1039/D3NA00540B10.1039/D3NA00540B ↗
22. 10.1021/acs.chemmater.5b0094410.1021/acs.chemmater.5b00944 ↗
23. Yang F. · Mater. Matters · 2020 · 14 · 4
24. 10.1039/C6CP00369A10.1039/C6CP00369A ↗
25. 10.1021/ja002776610.1021/ja0027766 ↗
26. 10.1038/natrevmats.2016.3410.1038/natrevmats.2016.34 ↗
27. 10.1021/ie50479a05410.1021/ie50479a054 ↗
28. Benzyl ether oxidation process https://patents.google.com/patent/CN111517928A/en(accessed: November 2024).
29. 10.1021/acsnano.7b0060910.1021/acsnano.7b00609 ↗
30. 10.1021/acsnano.7b0176210.1021/acsnano.7b01762 ↗
31. 10.1021/jo00320a05310.1021/jo00320a053 ↗
32. 10.1016/j.powtec.2014.01.08010.1016/j.powtec.2014.01.080 ↗
33. 10.1021/acs.chemmater.5b0103410.1021/acs.chemmater.5b01034 ↗
34. 10.1016/j.cplett.2006.08.04110.1016/j.cplett.2006.08.041 ↗
35. M.Bedzyk 361: Crystallography and Diffraction https://msecore.northwestern.edu/361/361text.xhtml(accessed: November 2024).
36. Vainshtein B. K. · 2013
37. 10.1021/cm100289d10.1021/cm100289d ↗
38. 10.1016/j.nanoso.2018.01.01210.1016/j.nanoso.2018.01.012 ↗
39. The Elongated Square Bipyramid https://www.qfbox.info/4d/J15(accessed: November 2024).
40. 10.1016/j.jallcom.2022.16515510.1016/j.jallcom.2022.165155 ↗
41. 10.1088/1742-6596/191/1/01203110.1088/1742-6596/191/1/012031 ↗
42. 10.1016/j.apsusc.2024.16026310.1016/j.apsusc.2024.160263 ↗
43. 10.1039/C9RA03488A10.1039/C9RA03488A ↗
44. 10.3390/nano1406054110.3390/nano14060541 ↗
45. 10.1039/C6CE02421A10.1039/C6CE02421A ↗
46. 10.1016/j.apsusc.2007.09.06310.1016/j.apsusc.2007.09.063 ↗
47. 10.1039/c0cc00736f10.1039/c0cc00736f ↗
48. 10.1021/acs.jpcc.8b0692710.1021/acs.jpcc.8b06927 ↗
49. 10.1016/j.surfcoat.2016.12.02410.1016/j.surfcoat.2016.12.024 ↗
50. 10.1016/j.mlblux.2021.10010510.1016/j.mlblux.2021.100105 ↗
51. Brow R. K. · Physics and Chemistry of Glasses · 1994
52. 10.3390/molecules2801020410.3390/molecules28010204 ↗
53. 10.1088/2043-6254/aa853a10.1088/2043-6254/aa853a ↗
54. 10.1016/j.proci.2014.06.11110.1016/j.proci.2014.06.111 ↗
55. 10.1021/ja00003a01910.1021/ja00003a019 ↗
56. 10.1021/ac60363a03410.1021/ac60363a034 ↗
57. 10.1002/advs.20180051410.1002/advs.201800514 ↗
58. 10.1002/sia.593310.1002/sia.5933 ↗
59. 10.1016/0368-2048(75)80047-810.1016/0368-2048(75)80047-8 ↗
60. 10.1016/0368-2048(76)80034-510.1016/0368-2048(76)80034-5 ↗
61. 10.7150/thno.4080510.7150/thno.40805 ↗
62. 10.1039/D3NA00709J10.1039/D3NA00709J ↗
63. 10.3109/0265673900914114410.3109/02656739009141144 ↗
64. 10.1080/02656736.2019.162831310.1080/02656736.2019.1628313 ↗
65. 10.1038/s41598-017-09897-510.1038/s41598-017-09897-5 ↗
66. 10.1063/1.368975110.1063/1.3689751 ↗
67. 10.1039/C5RA12558H10.1039/C5RA12558H ↗
68. 10.1021/nl301499u10.1021/nl301499u ↗
69. 10.1063/1.37299910.1063/1.372999 ↗
70. 10.1039/D0NA00134A10.1039/D0NA00134A ↗
71. 10.1039/C7CP08631H10.1039/C7CP08631H ↗
72. 10.1109/20.71853710.1109/20.718537 ↗
73. 10.1088/0957-4484/25/45/45200110.1088/0957-4484/25/45/452001 ↗
74. Nemati Z. · J. Appl. Phys. · 2015 · 117
75. 10.1016/j.jmmm.2010.01.00910.1016/j.jmmm.2010.01.009 ↗
76. 10.1021/acsomega.2c0596210.1021/acsomega.2c05962 ↗
77. 10.1016/j.jmmm.2010.02.04010.1016/j.jmmm.2010.02.040 ↗
78. 10.2174/138955751666616101311115510.2174/1389557516666161013111155 ↗
79. 10.1016/j.ijpharm.2009.07.03310.1016/j.ijpharm.2009.07.033 ↗
80. 10.1016/j.jconrel.2017.05.02810.1016/j.jconrel.2017.05.028 ↗
81. 10.7150/thno.2120910.7150/thno.21209 ↗
82. 10.1002/smll.20230627010.1002/smll.202306270 ↗
83. 10.3390/polym1422484710.3390/polym14224847 ↗
84. 10.1021/acs.chemmater.5b0312810.1021/acs.chemmater.5b03128 ↗
85. 10.1186/1556-276X-6-38310.1186/1556-276X-6-383 ↗
86. Fe3O4 Nanostructure Synthesis and Application https://www.rxlist.com/feraheme‐drug.htm#indications_dosage(accessed: November 2024).
87. 10.1002/smll.20210780810.1002/smll.202107808 ↗
88. 2D HF Magnetic Field Probe Operating Manual https://amflife.com/pdf/AMF‐probe‐operating‐manual.pdf(accessed: November 2024).
89. Measuring cell fluorescence using ImageJ https://theolb.readthedocs.io/en/latest/imaging/measuring‐cell‐fluorescence‐using‐imagej.html(accessed: November 2024).